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This article briefly outlines the current status of vascular surgery in Australia and New Zealand, reports on the future
practice and research challenges as perceived by vascular surgeons in our two countries, and finally, explores how the
current vascular surgical research efforts in Australasia map to those challenges. ( J Vasc Surg 2008;48:46S-52S.)Australia is a large island continent in the South Pacific
with a small population of approximately 21 million per-
sons. New Zealand is a small country of two islands, with a
smaller population of approximately 4 million persons.
Because the vascular surgery community in Australia and
New Zealand is a small group numerically, and somewhat
geographically remote, international interaction is essen-
tial, so we applaud the leadership of the World Federation
of Vascular Societies for providing this forum for interna-
tional interaction, and we would hope that long may it
continue and prosper.
This article will briefly outline the current status of
vascular surgery in Australia and New Zealand, report on
the future practice and research challenges as perceived by
vascular surgeons in our two countries, and finally, explore
how the current vascular surgical research efforts in Aus-
tralasia map to those challenges.
CURRENT STATUS OF VASCULAR SURGERY
IN AUSTRALASIA
Australian and New Zealand vascular surgeons have
long had a reputation for excellence and innovation and for
being world travellers in their quest for learning, to acquire
technical and research skills, and to share their surgical
expertise. This is perhaps no better exemplified than in the
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46Slast decade and a half during the endovascular revolution
when Michael Lawrence-Brown, James May, Geoff White,
and John Anderson have been at the forefront of develop-
ments in endovascular aortic repair. The early history of
vascular surgery in Australia and New Zealand has been
previously documented.1-4 Significant changes have oc-
curred in Australasian vascular surgery since the latter part
of the 1990s. These are summarized in Table I.
In 1997 an independent Board of Vascular Surgery,
separate from General Surgery, was established within the
Royal Australasian College of Surgeons (RACS) to oversee
vascular surgery training in Australasia. In the same year the
first FRACS (Vasc) examination was conducted. An inde-
pendent Board of Vascular Surgery has served the profes-
sion well and has allowed vascular surgery training and
curriculum changes to evolve rapidly and proactively as
alternative therapies and training needs have emerged. This
has been no more evident than in the area of endovascular
therapies. This flexibility saw the establishment of a direct
RACS Vascular Surgery training program in 2001, without
the need for a RACS General Surgery Fellowship. The
comprehensive nature of the current RACS Vascular Sur-
gery training program and examination process compared
with other countries is evident in the 2007 publication by
Cronenwett and Liapis5 where they surveyed vascular sur-
gery training and certification internationally.
Currently in Australia and New Zealand, 151 vascular
surgeons are Fellows of the Royal Australian College of
Surgeons (FRACS, Vasc), 138 in Australia and 13 in New
Zealand. In addition, a number of general and vascular
surgeons are in rural and regional practice, particularly in
New Zealand. In 2008, 48 vascular surgery trainees are at
various stages of the 5-year RACS Vascular Surgery and
Education Training program.
Vascular surgery in Australasia remains an attractive
career path, with the number of applications for training
positions far exceeding the number of available training
positions in 2008. Approximately seven trainees have grad-
uated each year since 2000 compared with 1985, when
there were only two graduates from the first iteration of the
JOURNAL OF VASCULAR SURGERY
Volume 48, Number 6S Walker 47Sdefined RACS Vascular Surgery training subspecialty,
which at that time consisted of 2 years of additional training
in vascular surgery after the completion of a 4-year RACS
General Surgery training program.
AConjoint Committee for the Recognition of Training
in Peripheral Endovascular Therapy was established in
2006.6 The Conjoint Committee is constituted by three
parent bodies, the RACS, the Royal Australasian College of
Physicians (RACP), and the Royal Australian and New
Zealand College of Radiologists (RANZCR). The parent
bodies have delegated to the Conjoint Committee powers
to formulate training guidelines in peripheral endovascular
therapy and to assess the training of persons seeking recog-
nition of their training in this area. Training in peripheral
endovascular therapy is assessed by the Conjoint Commit-
tee, usually in the context of the Specialist Advanced Train-
ing Programme of the RACS, RACP, or RANZCR. Rec-
ognition of satisfactory training is given after the successful
completion of Specialist Advanced Training.
A process for the recognition of prior training and
experience (Grandfathering Process), with a sunset clause,
has also been introduced with the establishment of this
Conjoint Committee.
Training requirements in peripheral endovascular therapy
demand a minimum of 100 angiograms and 50 peripheral
arterial interventions with the applicant as the primary proce-
duralist in 50% of cases. Carotid artery stenting requirements
encompass completion of peripheral endovascular therapy
training, knowledge of carotid stenting techniques and tech-
nology, competence in aortic arch angiography, the perfor-
mance of 25 carotid artery stenting procedures as the primary
Table I. Significant changes in the recent history of
Australasian vascular surgery
Year Event
1995 RACS Division of Vascular Surgery established
1997 Independent RACS Board of Vascular Surgery
established
1997 First FRACS (Vasc) Fellowship examination conducted
2001 ANZ Chapter of ISCVS renamed The Australian and
New Zealand Society for Vascular Surgery (ANZSVS)
2001 Direct RACS vascular surgery training programme
introduced
2002 ANZSVS takes over the functions of RACS Division of
Vascular Surgery
2002 Formal dissolution of RACS Division of Vascular Surgery
2006 Conjoint Committee for Peripheral Endovascular
Therapy established
2007 New TGA regulatory framework for medical devices
2008 Proposal that audit participation be required for
ANZSVS membership
2008 Australian Government Accreditation for Diagnostic
Imaging
ANZ, Australian and New Zealand; ISCVS, International Society of Cardio-
vascular Surgeons; FRACS, Fellow of the Royal Australian College of
Surgeons; RACS, Royal Australian College of Surgeons; TGA, Therapeutic
Goods and Administration; ANZSVS, Australian and New Zealand Society
for Vascular Surgery.proceduralist, and a preparedness to be involved in peer reviewoutcome audit of results. The Conjoint Committee will
shortly consider guidelines for the performance of compli-
cated endografting, which will include thoracic endovascu-
lar aneurysm repair (TEVAR) and branched and fenes-
trated aortic endografting.
In 2008 it has been proposed that one of the conditions
of membership of the Australian and New Zealand Society
for Vascular Surgery (ANZSVS) should be participation in
a Society-approved audit. This has been a requirement for
membership of the New Zealand Vascular Society for many
years.7
A trend has emerged in recent years toward greater
government involvement and regulation of the practice of
surgery, including vascular surgery, especially in Australia.
Examples of this include the Medical Services Advisory
Committee (MSAC) process for the evaluation of new
technologies,8 a new Therapeutic Goods and Administra-
tion (TGA) regulatory framework for medical devices,9 and
most recently, the introduction of Australian Federal Gov-
ernment Accreditation for Diagnostic Imaging.10
TheMSAC process for evaluation of new technologies,
which was established in 1998, aims to ensure that new and
existing medical procedures attracting Medicare Benefits
are supported by evidence of their safety, clinical effective-
ness, and cost-effectiveness.8 New technologies are not
funded by Medicare Benefits or private health fund reim-
bursement unless approved under this process. At this
stage, many of the newer endovenous technologies remain
unfunded, pending review under the process.
In 2007 a new TGA regulatory framework for medical
devices became effective9 that has made it more onerous
and expensive for companies to introduce new technologies
and to supply the same extensive range of devices and
goods that was available in the past. Already, as a conse-
quence of these changes, many valuable but low-volume
usage items are no longer available to the surgical community
because it has proven economically unviable for companies to
provide as extensive a range of products. Australian vascular
surgeons have concerns that this new regulatory environment
may stifle innovation and limit their early access to emerging
technologies.
The Australian Government Accreditation for Diag-
nostic Imaging10 commenced in 2008. Under this scheme,
all diagnostic imaging practices providing diagnostic imag-
ing services will need to be accredited by an approved
accreditation provider in order for Medicare Benefits to be
payable for the services they provide. This will include
vascular surgeons performing diagnostic imaging and en-
dovascular interventions.
FUTURE CHALLENGES FOR VASCULAR
SURGERY IN AUSTRALASIA
In preparation for this presentation, I conducted an
e-mail survey of the vascular surgery community in Aus-
tralasia seeking their views regarding:
1. The top three challenges for vascular surgery in Aus-
tralasia during the next 10 to 20 years.
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relating to vascular surgery that they would like an-
swered during the next 10 to 20 years.
The most important challenges for the next 10 to 20 years
listed by Australasian vascular surgeons are summarized in
Table II.
Vascular surgical workforce issues, training issues,
maintaining primacy as the vascular disease specialist, and
dealing with an increasing burden of vascular disease
brought about by an ageing population in the midst of an
epidemic of obesity, diabetes mellitus, and renal failure are
the key concerns for Australasian vascular surgeons. They
are also concerned about the availability of adequate fund-
ing and resources to deal with this burden of disease, and
about the potential for increasing government intrusion
and regulation of vascular surgeons’ daily practice.
Australia’s population, like that of manyWestern coun-
tries, is ageing as the baby boomer population bubble moves
through. Between now and 2047, it is projected that the
number of Australians of traditional working age (15 to 64
years) will rise by about one-fifth, older people (65 to 84
years)willmore than double, and the very old (85 years)will
more than quadruple.11 The profile of the health workforce
also continues to age: The proportion of those aged55 years
was 16% in 2006 compared with 12% in 2001.12
Although Australia is one of the healthiest nations in
the world, with an average life expectancy of 81.4 years now
second only to Japan,12 Australians are fatter than they have
ever been before. The prevalence of overweight and obesity
(body mass index 25.0 kg/m2, or waist circumference
80 cm for women or 94 cm for men) in Australian
adults is approaching 60% for both sexes and has more than
doubled in the past 25 years.13
Diabetes mellitus is on the rise in Australia, as it is across
the world, and according to estimates from the Australian
Diabetes, Obesity and Lifestyle Study, in 1999-2000 it
affected nearly 900,000 Australians aged 25 years.14 Re-
cent increases in the number of patients with diabetes have
led to claims that it has now risen to epidemic propor-
tions.15 The incidence of type 1 diabetes among Australian
children aged 14 years is increasing by 3% a year, but the
incidence in older children and adults seems to have stabi-
Table II. The top challenges for vascular surgery in
Australasia during the next 10 to 20 years as reported by
Australasian vascular surgeons
● Workforce/manpower/training
● Endovascular skills/endovascular suites/open skills
● Maintaining primacy as the vascular disease specialist
● Burden of Disease
● Aging Population
● Epidemic of obesity, diabetes, renal failure
● Funding/Costs Government intrusion
● Achieving national audit
● The future of academic surgerylized, according to a new report.16The number of new cases of treated end-stage kidney
disease has tripled in the past 25 years, from 22 per 100,000
population in 1981 to 74 in 2006.12 Between 2001 and
2005, there has been a 25% increase in the proportion of
new cases of end-stage kidney disease caused by diabetes.17
Although coronary and other heart diseases are the lead-
ing cause of death inAustralia, peripheral arterial diseases were
the 12th and 14th ranked contributing causes of death for
men andwomen, respectively, in Australia in 2005.12 Cardio-
vascular diseases as a group contributed to 55% of all deaths in
men and 60% of all deaths in women in 2005.12
Australia spent $1 in every $11 on health in 2005-
2006, equalling $86.9 billion or 9.0% of the gross domestic
product (GDP).12 As a share of its GDP, Australia spent
more in 2005 than the United Kingdom (8.3%), but much
less than the United States (15.3%).12 Australian govern-
ment spending on health is projected to increase as a
proportion of GDP from 3.8% in 2006-2007 to 7.3% in
2046-2047.11
All these issues have an impact on vascular surgeons.
There are concerns of a looming manpower crisis in vascu-
lar surgery in Australasia. Whether this eventuates remains
to be seen. Unfortunately, workforce manpower planning
is hazardous at best, and the data on which to base pro-
jected needs is often only a best guess and potentially
subject to rapid change. The suggestion that there will be
an ongoing increase in the number of patients with periph-
eral vascular diseases requiring treatment—but inadequate
numbers of vascular surgeons to cope with the demand—
has also been made in the United States.18 The manpower
concern currently is more often raised in the context of deliv-
ery of emergency and after-hours vascular services rather than
for elective services. Already many vascular surgeons have
commented on an increasing acute and after-hours workload
with older, sicker, and more complex patients.
The coexistence of a move towards government and
Australian Medical Association–recommended safe work-
ing hours19 and a societal change in favor of better life–
work balance amongst younger surgeons who balk at work-
ing intensive after-hours call schedules is already posing
difficulties in providing sustainable acute vascular surgical
services, even in major tertiary referral hospitals. This issue
is even more evident in regional centers, where there may
be only one or two vascular surgeons. The additional
emerging problem, again most evident in regional centers,
relates to the provision of emergency general surgical and
trauma services. Subspecialty trained surgeons increasingly
decline to participate in these on-call rosters, citing a lack of
a general surgical qualification or adequate recent general
surgical experience. This is a direct consequence of increas-
ing surgical subspecialization, as demonstrated by direct
vascular surgery training without the need for general sur-
gery training. Restoring the balance in this regard is under
consideration by the RACS Board of Vascular Surgery, with a
proposal for a dual General and Vascular Surgery Fellowship
comprising 4 years of general surgery training and 3 years of
vascular surgery trainingwith separate examinations in general
surgery (year 5) and vascular surgery (year 7).
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vascular surgeons, about whether trainees are now ade-
quately trained inmajor open vascular surgery. The greatest
concern relates to open aortic surgery, because some cen-
ters in Australasia undertake up to 70% of abdominal
aortic aneurysm (AAA) repairs by EVAR, and in most cen-
ters, TEVAR has become the treatment of choice for most
thoracic aortic pathologies. Fellowships in open aortic sur-
gery, after the completion of standard vascular surgery train-
ing, are being considered in some centers, such is the concern.
Conversely, although current trainees are generally well
trained in endovascular techniques, there are concerns
among more senior surgeons about how they can be re-
trained and adopt endovascular techniques into their prac-
tice. Debate is occurring about whether the vascular sur-
gery service of the future can expect all individuals to be
equally proficient in all aspects of vascular care. Some have
suggested that a future vascular service might consist of a
group of vascular clinicians who, much like what has oc-
curred in cardiology practice, concentrate in selected areas;
for example, open surgery, complex aortic surgery, basic or
complex endovascular surgery, vascular imaging, and vas-
cular medicine. Most recently, discussion has turned to the
issues of how skills can be maintained, particularly for
low-volume interventions, and how and how often recre-
dentialing should occur. How to manage the failing or
underperforming surgeon remains problematic.
Turf wars and concerns about maintaining primacy as
the vascular disease specialist continue. Currently in Aus-
tralasia, the turf wars vary from region to region, depending
on local personnel and access to and availability of facilities.
The battle with radiologists has mainly been about access to
angiosuites in the public hospital system, where historically,
the angiogsuite has been the domain of the radiology
department. What is clear is that young vascular surgeons
graduating from training programs and equipped with
endovascular skills expect access to angiosuites and endo-
vascular facilities as a matter of course, and they will not
accept appointments at institutions where access to these
facilities is not provided. This is no longer an issue in the
private sector where vascular surgeons trained in endovas-
cular techniques are readily credentialed and provided with
access to the endovascular facilities they require. The cur-
rent facilities challenge in Australasia is to populate vascular
surgery operating theaters with state of the art hybrid
operating endovascular suite facilities.
Radiologists are not currently considered amajor threat
in terms of primacy as the vascular disease specialist in
Australasia. This is because at present, radiologists are not
primary care physicians, do not have comprehensive train-
ing in vascular diseases, do not have hospital admitting
rights, and rely on referrals from other practitioners. There
are moves to change this, however.
Cardiologists are currently perceived as a greater threat
to the established order because they have access to patients
who have systemic atherosclerotic disease, they have access
to facilities with their own cardiac catheterization laborato-
ries, and they have high-level catheter skills. Prompted bythe example of many cardiologists in the United States, a
number of Australasian cardiologists have embarked on the
endovascular treatment of peripheral, carotid, and renal
artery disease in particular.
Australasian vascular surgeons currently believe that
with their comprehensive training and their ability to offer
the full range of open, endovascular and medical therapies,
that they are well placed to maintain their principal role in
the management of patients with vascular diseases. To
ensure that this occurs and for vascular surgeons to maintain
primacy and credibility in the field of vascular diseasemanage-
ment, it will be important for vascular surgeons and the
Australian and New Zealand Society for Vascular Surgery
(ANZSVS) to develop a greater profile in the community and
with the general practitioner referral base, to market and
promote ourselvesmore widely in the community, to become
more politically proactive, and to monitor and report on our
results as part of a national audit or vascular registry. These are
lessons that our US colleagues and the American Vascular
Association have already taken on board.
RESEARCH CHALLENGES FOR VASCULAR
SURGERY IN AUSTRALASIA
The most important research questions listed by Aus-
tralasian vascular surgeons for the next 10 to 20 years are
summarized in Table III. These are not unique to Australa-
sia and are probably generally reflective of the research
issues that would be proposed worldwide. There is a clear
desire for a better understanding of the basic biology of the
broad spectrum of vascular pathologies, including ather-
oma, restenosis, AAA, and aortic dissection, in particular.
The hope is that such knowledge might translate to alter-
native medical or gene therapies to prevent or ameliorate
the progression of these disease processes before invasive
intervention is required. In addition, better knowledge of
the basic biology and factors that precipitate symptomatic
events, such as plaque rupture, aneurysm progression and
rupture, aortic dissection, and dissection expansion might
allow better timed and targeted invasive interventions.
There is a desire to further refine selection criteria and
follow-up protocols for EVAR. Australasian vascular sur-
geons, who have had access to most available endovascular
devices, see an ongoing need for better devices, particularly
for thoracic aortic interventions, where the currently avail-
able TEVAR devices have varying limitations in dealing
with much of the anatomy confronted. There is a desire to
better define the appropriate use of endovascular tech-
niques for a variety of other indications, including claudi-
cation due to superficial femoral artery disease, carotid
stenosis, aortic dissection, renal artery disease, and varicose
veins. The yearning for smaller diameter and better func-
tioning prosthetic grafts for peripheral arterial reconstruc-
tion and arteriovenous access creation remains unfulfilled.
Similarly, the desire for alternative therapies for the non-
reconstructible limb remains at the forefront of Australasian
vascular surgeons’ wish list.
When the current research being undertaken by Aus-
tralasia’s vascular surgeons is examined, the research activ-
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Australasia’s vascular surgeons continue to push the
boundaries of endovascular aortic repair for ever more
complex disease, particularly of the thoracic and thoraco-
abdominal aorta, and for infrarenal aortic disease with
complex iliac anatomy.20-24 Australasia’s surgeons are par-
ticipating in device trials for acute thoracic aortic dissec-
tion,25 and funding is being sought to establish a registry to
monitor the outcomes of TEVAR for traumatic thoracic
Table III. The main research questions relating to
vascular surgery that Australasian vascular surgeons would
like answered during the next 10 to 20 years
Atherosclerosis/restenosis/inflammation
● Better understanding and management of atherosclerosis,
restenosis, and inflammation
● Improved identification and stabilization of at-risk plaque with
medical measures
● Improving medical therapy, gene therapy, and testing
● Develop better anticoagulants and antiplatelet therapy
● Define optimal cardiac investigation and management before
vascular intervention
Aortic Disease
● Understanding basic biology of AAA and other aortic disease
● Define a medical management for AAA to prevent
development, expansion and rupture
● Determine the appropriateness of intervention for small AAA
in young patients
● Better define indications and predict outcomes for EVAR
● Develop better/optimal EVAR and TEVAR devices
Peripheral Arterial Disease
● Develop better medical therapy for PAD
● Better understanding of exercise therapy for PAD
● Define appropriate use of endovascular techniques and
appropriateness of intervention for claudication, especially in
the SFA
● Institute a national database to accurately assess performance
of interventions
● Develop alternative therapies for the non-reconstructible limb
● Define role of gene therapy/angiogenesis
● Improving quality of life for PAD patients
● Better understand and manage metabolic syndrome/diabetic
foot
● Develop alternative conduits and small diameter grafts
● Define role and means of surveillance after intervention
Carotid disease
● Define best treatment for carotid stenosis (medical/CEA/
CAS)
● Identify criteria for asymptomatics that require invasive
intervention
● Define appropriate role of carotid stenting
Renal
● Define the best management for renal artery disease
● Develop more durable AV dialysis access options
Venous
● Define role of endovenous techniques and surgery for varicose
veins
● Develop durable interventions for the deep venous system
AAA, Abdominal aortic aneurysm; CAS, carotid artery stenting; CEA,
carotid endarterectomy; EVAR, endovascular aneurysm repair; PAD, pe-
ripheral arterial disease; SFA, superficial femoral artery; TEVAR, thoracic
endovascular aneurysm repair.aortic tear. A number of groups have active research pro-grams examining the prevalence, biology, and genetics of
aortic and peripheral arterial diseases in an effort to define
roles for screening and possible medical interventions.26-37
Recently, a helpful interactive model to predict out-
comes of EVAR has been developed after analysis of the
longitudinal Australian audit of EVAR.38 This interactive
model that is available for download can be used in day-to-
day patient consulting for counselling and preoperative
decision making. The model uses eight preoperative vari-
ables (aneurysm size, age, American Society of Anesthesi-
ologists score, gender, creatinine, aortic neck angle, infra-
renal neck diameter, and infrarenal neck length) to predict
the likely outcomes of EVAR, including perioperative mor-
tality, perioperative morbidity, medium-term survival and
reintervention rates.39 Five of the variables are available
before any imaging and can be used to provide preliminary
risk estimates. Funding has been sought to enable this
model to be validated prospectively using a new cohort of
Australasian EVAR patients.
A number of groups are active in peripheral artery disease
research covering such as areas as medical therapy,40 exercise
therapy for claudication,41-43 and brachytherapy to inhibit
restenosis after femoral angioplasty.44 There is a desire to
establish a national database to accurately assess performance
of femoral artery interventions (open, endovascular, andmed-
ical therapies) with outcomes to also include quality of life
assessment in addition to the traditional hard end points of
vessel patency and limb salvage rates.
The patient with critical limb ischemia who has ex-
hausted reconstruction options because of lack of suitable
conduit or because of the non-reconstructible pattern of
their arterial disease remains a major challenge for vascular
surgeons. Australasian vascular surgeons are involved in a
number of research efforts that may offer hope in this area.
A number of centers are involved in trials of angiogenesis for
patients with severe non-reconstructible peripheral arterial
disease.45 Efforts continue to develop a tissue-engineered
vascular graft, grown in the peritoneal cavity on silastic
tubes, which could be used for arterial revascularization or
as an arteriovenous access conduit.46,47 This methodology
has recently been used to grow myofibroblast-rich tubular
structures and tissue capsules for use as autologous grafts
for hollow, smooth muscle–walled visceral organs, includ-
ing the bladder, uterus, and vas deferens.48
Most recently, investigators in Sydney have com-
menced a program of hyperperfusion for peripheral artery
disease patients facing amputation, theHypertensive Extra-
corporeal Limb Perfusion (HELP) study.49 An extracorpo-
real cardiac ventricle assist pump is used to increase the
intra-arterial pressure in the femoral artery proximal to an
occlusion. This increase in distal pressure is claimed to
increase flow through collateral vessels. Preliminary results
of this therapeutic trial are to be published shortly.
CONCLUSION
Vascular surgery in Australasia in 2008 is in a healthy
state. At the same time, however, numerous issues regard-
ing the vascular surgical workforce, training, credentialing,
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will retain their principal role in managing patients with
vascular diseases loom large. An independent RACS Board
of Vascular Surgery overseeing a vascular surgical training
program that has been adaptable to the ever-changing field
of vascular disease management has served the profession
and our patients well. Coupled with a strong and proactive
ANZSVS, and with research efforts well mapped to the
relevant vascular research questions, we can look forward
with confidence to dealing with the emerging issues and the
increasing burden of vascular disease that is on the horizon.
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Dr Enrico Ascher (Brooklyn, NY). Is competition from other
surgical and nonsurgical specialties of concern to the Australian
vascular surgeons?
Dr Philip J. Walker. Yes, I think, as I alluded to, one of the
major issues in terms of practice in Australia and New Zealand is
political. Other specialties are trying to move into our area, partic-
ularly cardiologists, less so radiologists; but other groups, for
example vascular sonographers, show now some movement for
independence, where previously they have worked in concert with
vascular surgeons. Also, podiatric surgeons are attempting tomove
into the management of diabetic foot disease. Additionally, there is
a big push from the universities and from government for a role
substitution across medicine and not just in the vascular area.
I suppose cardiologists are perceived as the biggest threat indisease profile, they have catheter skills, and they have access to
facilities. Radiologists in Australia aren’t primary care physicians.
They don’t have admitting rights in hospitals, so they actually work
on a referral basis; so they are seen as less of a threat.
I suppose having had an independent board and independent
flexible training system that has been able to evolve, Australian
vascular surgeons now are extremely well trained in endovascular
techniques and really we see ourselves in good position to with-
stand these pressures as they arise.
Dr Henrik Sillesen (Copenhagen, Denmark). I guess the
issue of the cardiologists is something that everybody knows about.
I just recently heard a good answer to give a cardiologist when they
ask if you need help with something, with balloons, you just ask
them back if they need help with the coronaries; and then it kind of
stops there, I think.
